Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

(b) On December 29, 2016, David-Alexandre C. Gros, M.D. notified Alnylam Pharmaceuticals, Inc. (the “Company”) of his intention to resign from his positions as the Company’s Senior Vice President, Chief Business Officer and Principal Financial Officer, effective as of January 6, 2017, due to his personal interest to return to the West Coast in a broader operating role.

(c) On January 3, 2017, the Company’s Board of Directors (the “Board”) appointed Michael P. Mason as the Company’s Principal Financial Officer, effective as of January 6, 2017. Mr. Mason currently serves as the Company’s Vice President, Finance and Treasurer and Principal Accounting Officer.

Mr. Mason, 42, has served as the Company’s Vice President of Finance and Treasurer and as the Company’s Principal Accounting Officer since February 2011, and previously served as the Company’s Principal Financial Officer from February 2011 to June 2016. From December 2005 to February 2011, Mr. Mason served as the Company’s Corporate Controller, and from August 2009 to February 2011, as the Company’s Senior Director of Finance. From June 2006 to July 2009, Mr. Mason served as the Company’s Director of Finance. From May 2000 through November 2005, Mr. Mason served in several finance and commercial roles at Praecis Pharmaceuticals Incorporated, a public biotechnology company, most recently as Corporate Controller. Prior to Praecis, Mr. Mason worked in the audit practice at KPMG LLP, a national audit, tax and advisory services firm. Mr. Mason has an MBA and is a certified public accountant.

On December 30, 2016, Mr. Mason was granted 8,502 restricted stock units under the Company’s Amended and Restated 2009 Stock Incentive Plan, as amended (the “2009 Plan”), as approved by the Compensation Committee of the Board. The restricted stock units will vest in full on December 30, 2017, subject to Mr. Mason continuing to be an eligible participant under the 2009 Plan at such time.


About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases. Its Genetic medicines include Patisiran (ALN-TTR02) and Fitusiran (ALN-AT3), and additional genetic programs, including ALN-AAT.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Recent Trading Information

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) closed its last trading session down -0.01 at 38.63 with 819,306 shares trading hands.